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Animal experiments are generally conducted at higher dose levels than anticipated human dose
levels in order to elicit otherwise subtle changes in reproduction or developmental effects with rela-
tively few animals. Based on animal data, regulatory strategy generally has been to postulate a no-ob-
served-effect level (NOEL) for toxic effects and to divide this by a safety factor, usually 100, to esta-
blish acceptable levels for humans. Various authors have discussed the shortcomings of using NOEL
and have suggested the use of an estimable effect level determined from a dose-response curve fitted
to bioassay data, e.g., the dose at which 1% of the animals are adversely affected, and employing
some form of conservative low dose extrapolation to control risks at lower doses. In this paper, 10
sets ofbioassay data on fetal mortality or anomalies were used to compare the estimated upper limits
of risk estimated at the NOEL/100 and the lower 95% confidence limit estimate of the dose produc-
ing adverse effects in 1% of the embryonic implants or fetuses divided by 100 (LEDO /100). The lat-
ter quantity is expected to result in a risk (proportion affected) of less than 10-4 (1 in 10,000). The
estimated upper limits of risk associated with the NOEL/100 were from 2 x 10-4 to 6 x 10-4 for the
10 data sets investigated.
Introduction
In order to detect potential toxic effects with a limited
number of animals, experimental studies typically
employ doses that are higher than expected human
exposure levels. Thus, high to low dose extrapolation is
generally required. The following discussion of
extrapolation of developmental toxicity data does not
discount the possibility of a biological threshold below
which no risk exists.
One approach for setting acceptable levels for
developmental toxicity risk has been the use of safety
(uncertainty) factors. From a bioassay conducted at
several dose levels (generally three or more), a suppos-
edly safe dose for humans is determined by dividing
the no-observed-effect level (NOEL) by a safety factor.
Lehman and Fitzhugh suggested a safety factor of 100
(1). If the NOEL is taken to be a safe dose for the
experimental animals, a safety factor of 10 is applied to
allow for potentially higher sensitivities of humans
compared to the experimental animals and another
factor of 10 to allow for differences in sensitivities
among individuals. For irreversible effects, such as
death or malformation, an additional safety factor of 10
is suggested (2). Even if a safety factor of 100 is adequate
to account for interspecies and intraspecies differences
in response, this does not necessarily result in a risk-
free dose. The NOEL may not represent a safe dose for
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the laboratory animal tested because the power of the
experiment may be inadequate to detect subtle toxic
effects. That is, the NOEL may have been inadequately
established. Also, the safety factors are somewhat arbi-
trary and may be adequate on the average, but may be
inadequate for any particular case. Further, Gaylor (3)
and Crump (4) discuss the problem of poorer experi-
ments resulting in higher NOEL's and hence higher
allowable levels.
Rather than routinely applying a fixed size safety
factor to the NOEL of the critical toxic effect in an ani-
mal species to obtain a safe dose, data from the whole
dose-response curve should be used in setting acceptable
levels for humans that are estimated to be without any
appreciable risk. Based upon the upper confidence limit
on the risk estimated from the animal dose-response
data, the size of the safety factor can be determined to
reduce the risk below a certain level for the animal test
species (3).
Several mathematical dose-response models have
been used for curve fitting of experimental data.
Crump applied modifications of the one-hit and
multistage models to determine a benchmark dose to
replace the NOEL (4). Abenchmark dose was suggested
for which the excess risk was estimated not to exceed 1
to 10%, with 95% confidence. Dourson et al. suggested a
similar approach (5). For carcinogenic data, Mantel
and Bryan (6), Van Ryzin (7), and Farmer et al. (8),
suggested estimating the dose that produced an excess
tumor incidence of 1% (EDO1) and then using someD. W GAYLOR
form of conservative extrapolation from that point for
lower doses. Gaylor suggested using safety factors in
conjunction with the EDO1 for controlling risks at low
doses foranytoxic effect (3).
Regardless of the dose-response model used, it will
generally be difficult to estimate with precision an ex-
cess risk of less than 1 to 10% above the spontaneous
background level for quantal responses, e.g., the pro-
portion of implants that are resorbed or the proportion
of live fetuses with a type of malformation, from
standard developmental toxicity studies.
Kimmel and Gaylor suggest a procedure based on
the ED10 for controlling low dose risks (9). A dose-
response curve is fitted to the experimental data on the
proportions affected. This curve is used to estimate the
dose that produces a low level of risk in the experi-
mental dose range, e.g., the ED10 (the effective dose cor-
responding to an excess risk of 10%). Then, a lower
confidence limit on the dose that produces a 10% risk
(the LED10) is obtained. IfFrepresents a safetyfactor, at
a dose of LED1O/F, the risk in the low dose region is
estimated to be less than 0.1/F. This procedure is con-
servative from a safety standpoint when the dose re-
sponse is curving upward (convex). If a biological
threshold exists, the lower limit on risk would be zero
if the LED1o/F is less than the threshold dose. This
procedure makes greater use of the dose-response data
collected in animal studies, whereas the current proce-
dure based on the NOEL makes use of only a single
point. The advantage of applying safety factors to the
LED10, or some other estimable dose, is that an upper
limit on the risk can be estimated, whereas application
ofa safety factor to the NOELresults in variable levels of
risk since the potential risk at the NOEL is not
considered.
Most teratological studies are capable of detecting
disease incidence of 10% or more. Hence, the NOELwill
generally represent a dose at which the risk is less than
10%. It generally is possible with a slight extrapolation
to estimate the ED01. Since the EDO1 is generally in the
dose range ofthe NOEL, it is of interest to compare the
LEDo1/100 and the NOEL/100. Generally, the EDO1
will not be directly measurable in a typical teratology
study and requires some interpolation or extrapola-
tion from the experimental doses. In general, the choice
of the model will not have much impact on the
estimation of the ED01. Rather than use the NOEL/100
to set acceptable levels, which can vary considerably
depending upon the experimental design, a more con-
sistent approach is to divide the lower confidence limit
on theEDO1 ofagiven effect, i.e., theLEDO1, by 100. Ifthe
dose response is curving upward in the low-dose
region, the risk at the LEDo1/100 is estimated to be less
than 10-4 (1 in 10,000). If the LEDo1/100 is less than a
threshold dose, ifone exists, then the risk is zero.
Methods
Ten sets of dose response data for the proportions of
fetuses with reproductive or developmental defects were
investigated to compare the NOEL/100 and LEDo1/100
procedures (Table 1). In general, it would be preferable
to use data on a litter basis. Since the data were not
reported for individual litters, dose-response curves on
the proportions of dead or abnormal fetuses per litter
were not obtained and quantal data on a fetal basis were
used.
An exponential polynomial model was fitted to each
ofthedatasets:
P= 1 -exp[-(bo +bld+ b2d2 +. . .+bkdk)
where Pwas the proportion ofaffected fetuses, dwas the
dose rate, and each b was estimated from the data using
the procedure of Howe and Crump (10). These esti-
mated sigmoidal dose-response curves were only used
to provide an estimate ofthe LEDO1. Since the estimated
dose response is not used for low dose extrapolation, a
biologically based model is not particularly important,
and all that is required is a descriptive model in the
experimental dose range.
Conservative upper limits on low dose risk estimates
are obtained for convex (upward curvature) dose-
response curves by using a risk to dose slope of
0.01/LED01, belowtheLEDO1, i.e.,
Estimated risk < . .01 x dose. LED01
Thus, the risk at the LEDo1/100 is estimated to be less
than 10-4 (1 in 10,000). The risk at the NOEL/100 is
estimated tobe lessthan 10-4 x NOEL/LEDO0. There is
a difference of opinion as to the NOEL from those
given by Crump (4) for ethylenethiourea and 2,3,7,8-
tetrachlorodibenzo-p-dioxin (intestinal anomalies),
indicating one of the difficulties of basing procedures
on the NOEL.
Results and Discussion
Comparison of the NOEL and the LEDO1 for the 10
data sets is shown inTable 2. The NOELwas afactor of2
to 6 times the LEDO1, resulting in estimated upper
limits of risks at the NOEL/100 to be 2 to 6 times high-
er than the estimated upper risk of 10-4 at the LEDo1/
100. Due to the lack of detail of the published data, the
issue of litter effects could not be addressed. Ignoring
the differences among litters could result in a reduced
estimate of the variance. Hence, the LEDO1 values re-
ported are larger than would be obtained when the
variation of litters is properly included. Thus, the
NOELs forthese 10 data sets are actually more than 2 to
6 times greater than the LEDO1 values that would be
obtained if interlitter variation were included.
The approach presented here for extrapolating risk to
low dose levels based upon the LEDO1 takes into account
the dose-response data. Therefore, it provides a stronger
basis on which to estimate risk for low dose levels. More
research is needed for developing appropriate dose-
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Table 1. Experimental proportions ofaffected animals (quantal data).
Compound Species Effect Doses Number
Ethylenethiourea (11) Rats Fetal anomalies 0 mg/kg 0/167
2,3,7,8-Tetrachlorodibenzo-p-dioxin (12)
2,3,7,8-Tetrachlorodibenzo-p-dioxin (13)
Calcium valproate (14)
Ametantrone (15)
Linamarin (16)
Solanidine (17)
Paraxanthine (18)
Rats
Rats
Rabbits
Rabbits
Hamsters
Hamsters
Mice
Intestinal anomalies
Fetal mortality
Skeletal malformations
Malformations
Skeletal defects
Resorbed fetuses
Limb anomalies
Palate anomalies
Eye anomalies
aNOEL.
5
loa
20
40
80
0 jAg/kg
0.125
0.250a
0.500
1.00
0 jAg/kg/day
0.001a
0.010
0 mg/kg
50
isoa
350
0 mg/kg
0.2a
0.4
0.8
0 mg/kg
70a
100
120
140
< 1 mg/kg
22
66a
110
0/132
1/138
14/81
142/178
24/24
0/24
0/38
1/33
3/31
3/10
22/318
16/224
17/100
3/93
7/136
2/95
35/83
3/92
2/55
6/66
8/68
1/67
0/55
5/56
10/54
14/63
90/1054
26/312
49/464
70/235
0 mg/kg
175a
300
0
175a
300
0
175a
300
0/114
2/87
32/91
0/114
1/87
30/91
0/114
0/87
9/91
Table 2. Estimated upper limits on reproductive or developmental risk at the NOEL/100.
Estimated risk
Chemical Species End point LEDol/lOOa NOEL/100 at NOEL/100
Ethylenethiourea Rat Anomalies 0.062 0.100 < 1.6 x 10-4
2,3,7,8-Tetrachlorodibenzo-p-dioxin Rat Intestinal 0.0004 0.0025 < 6.2 x 10-4
2,3,7,8-Tetrachlorodibenzo-p-dioxin Rat Mortality 5.4 x 10-6 10.0 x 10-6 < 1.9 x 10-4
Valproate Rabbit Skeletal 0.41 1.50 < 3.7 x 1V-4
Ametantrone Rabbit Malformations 0.0005 0.0020 < 4.0 x 10-4
Linamarin Hamster Skeletal 0.20 0.70 < 3.5 x 10-4
Solanidine Hamster Resorptions 0.25 0.66 < 2.6 x 10-4
Paraxanthine Mouse Limb 0.29 1.75 < 6.0 x 10-4
Palate 0.32 1.75 < 5.5 x 10-4
Eye 0.46 1.75 < 3.8 x 10-4
aEstimated risk at the LEDol/100 is 10-4.
response models for these types of data. Improved
statistical curve-fitting procedures of experimental
data can provide better estimates of the LEDO1. For the
reproductive and developmental effects examined here,
the use of a 100-fold safety factor applied to the NOEL
resulted in estimated risks ofless than 6 x 10-4. The risk
of reproductive or developmental effects is estimated to
be less than 10-4 at the LEDo1/100 in the animal test
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systems. Thus, a lower level of risk can generally be
obtained by using the LEDo,/100 rather than the
NOEL/100 to set allowable dose levels. Iflower levels of
potential risk are desired, then larger safety factors
mustbe used.
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